Ferrer M, Sanz M L, Sastre J, Bartra J, del Cuvillo A, Montoro J, Jáuregui I, Dávila I, Mullol J, Valero A
Departamento de Alergia e Immunología Clinica, Clinica Universidad de Navarra, Pamplona, Spain.
J Investig Allergol Clin Immunol. 2009;19 Suppl 1:19-24.
Recombinant and purified allergens are currently available for determining specific IgE targeted to different allergenic components. In this way it is possible to diagnose the sensitization profile of each individual patient. The microarray technique makes it possible to determine specific IgE against multiple allergens simultaneously in one same patient, with a minimum amount of serum, and even allows the determination of IgG and IgM against the same allergens in one same serum sample. Microarray procedures are being developed not only for the determination of antibodies but also for cell activation tests. In addition, microarray technology will help explain cross-reactions, and will facilitate the evaluation of subjects in which skin tests cannot be performed. These techniques will allow a great step forward in the development of immunotherapy specifically targeted to the sensitizations found in each individual patient, yielding especially hypoallergenic forms of great immunogenic capacity, and thus improving the safety and efficacy of immunotherapy. Lastly, microarrays will improve our understanding of the physiopathology of allergic diseases.
目前已有重组和纯化的变应原可用于测定针对不同变应原成分的特异性IgE。通过这种方式,可以诊断每个患者的致敏情况。微阵列技术能够在同一患者中同时以最少的血清量测定针对多种变应原的特异性IgE,甚至还能在同一血清样本中测定针对相同变应原的IgG和IgM。微阵列程序不仅用于抗体测定,还用于细胞活化试验。此外,微阵列技术将有助于解释交叉反应,并便于对无法进行皮肤试验的受试者进行评估。这些技术将在针对每个患者所发现的致敏情况进行特异性免疫治疗的开发方面取得巨大进展,产生具有强大免疫原性的低变应原性形式,从而提高免疫治疗的安全性和有效性。最后,微阵列将增进我们对过敏性疾病生理病理学的理解。